PhotoMedex, Inc. (NASDAQ: PHMD) provides novel solutions designed for application in the areas of dermatology, therapeutic skin care and surgical products & services. The company is currently developing proprietary excimer laser and fiber-optic systems to treat dermatological applications such as psoriasis and vitiligo. PhotoMedex’s XTRAC® was the first FDA market-cleared excimer laser system designed to treat dermatological applications such as psoriasis and vitiligo. For further information, visit the Company’s web site at www.photomedex.com.
- 16 years ago
QualityStocks
PhotoMedex, Inc. (NASDAQ: PHMD)
Tags Rodman & Renshaw
Related Post
-
D-Wave Quantum Inc. (NYSE: QBTS) Expands Quantum Optimization Offerings to Accelerate Commercial Adoption
At its Qubits 2025 user conference, D-Wave introduced new hybrid solver capabilities supporting continuous variables…
-
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
An increase in deaths from COVID-19 underscores the persistent danger of the virus and the…
-
Thumzup Media Corp. (NASDAQ: TZUP) Continues Building Its Client Base with Its Proprietary Tech for Ad Campaigns
Social media commerce is expected to grow to $821 billion in 2025[1], demonstrating its importance…